Aizon – an AI SaaS provider that transforms pharmaceutical manufacturing operations – announced that it has closed $20 million in Series C funding led by NewVale Capital. And existing investors Atlantic Bridge, Crosslink Capital, and Uncork Capital also participated in the round.
This funding round – combined with the continued support of key investment partners – will enable Aizon to significantly scale, accelerate its development pipeline, and better serve its customers And Aizon utilizes advanced predictive analytics, artificial intelligence, and other smart factory technologies to provide the most powerful and accessible GMP AI platform for pharmaceutical manufacturers.
Through Aizon, customers unlock next-generation insights and enhanced decision-making capabilities and can discover new optimization paths, reduce costs, predict deviations, and enhance their manufacturing systems. And Aizon prioritizes rigorous quality and compliance and follows GAMP5 for GMP processes to ensure compliant data acquisition, storage, and consumption.
KEY QUOTES:
“This investment is pivotal to the future growth of our company as it validates the success of our platform and enables us to better execute on our strategic roadmap. With this additional capital and the support of our partners, we can accelerate the launch of our innovative eBR solution in Q3 2024. We are excited to introduce this transformative solution, underscoring our commitment to continually advancing our offerings and empowering our customers with the most effective, cutting-edge technologies.”
– Pep Gubau, Aizon CEO and co-founder
“Aizon’s AI-driven solutions are poised to redefine pharmaceutical manufacturing and we are excited to play a role in this next chapter, as the company continues to grow and transform this industry. Our focus is on companies that serve the pharmaceutical space with a proven business model and strong value proposition to their customers, and Aizon exemplifies the type of partner we’re looking for.”
– Todd Holmes, managing partner at NewVale Capital
